Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award
September 18 2023 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced Stephen Dilly, MBBS, PhD, President and Chief
Executive Officer of Codexis, has been named a finalist for the
prestigious 2023 Bloom Burton Award. Bestowed annually and
nominated by the public at large, the Bloom Burton Award honors an
individual who made the greatest contribution to Canada’s
innovative healthcare industry the previous year. Dr. Dilly has
been recognized for his leadership of Vancouver-headquartered
Sierra Oncology, where he led the company through the Phase 3
clinical development of momelotinib and its drive toward
commercialization as well as the company’s $1.9 billion acquisition
by GSK.
“It is an honor to be named as a finalist for the 2023 Bloom
Burton Award. Leading the team at Sierra Oncology to bring
momelotinib to the patients who would most benefit was an
energizing experience and a highlight of my career. GSK recognized
the value of the compound the same way we did and joined forces
with us to help accelerate delivery to patients on a global scale,”
said Dr. Dilly. “I am incredibly grateful to the physicians and
patients who participated in our clinical trials, and the entire
team at Sierra who worked diligently to meet demanding timelines
throughout the development process. This nomination is a
recognition of the work of the entire team and our collective
vision to transform promise into patient impact.”
The Bloom Burton Award finalists and winner are chosen by an
independent panel of judges consisting of international leaders in
healthcare investment, entrepreneurship and journalism. The winner
will be announced live at the Bloom Burton Award Gala on September
28, 2023, at the Four Seasons Hotel Toronto. For more information,
please visit www.bloomburton.com/gala.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® technology platform to discover, develop
and enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing and
nucleic acid synthesis, and the Company is currently developing its
proprietary ECO Synthesis™ platform to enable the scaled
manufacture of RNAi therapeutics through an enzymatic route.
Codexis’ unique enzymes can drive improvements such as higher
yields, reduced energy usage and waste generation, improved
efficiency in manufacturing and greater sensitivity in genomic and
diagnostic applications. For more information,
visit https://www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae806bb-f003-408b-8f68-d17276433729
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024